Dr Silvia Stacchiotti from Milan has published her paper, “Sirolimus in Advanced Epithelioid Hemangioendothelioma”, in the Annals of Surgical Oncology. This paper is a retrospective analysis of the effects of Sirolimus, based on the Italian Rare Cancer Network database.
The analysis was conducted on cases involving generally advanced EHE. While it is clearly not a drug that works in all cases, the effects of Sirolimus (and Everolimus) on EHE at intermediate levels of progress are encouraging, and appear to be statistically more beneficial than other drugs. In addition, the combination of Sirolimus (and Everolimus) with anti angiogenic drugs (like Pazopanib or Vandetanib) have also had beneficial effects on more advanced EHE.
With the beneficial effects seen in several cases, the EHERCC was pleased to see the continued focus on the evaluation of the use of this drug to combat EHE. It is also hoped that the work being carried out by Dr Rubin may provide insights into the possible genetic differences between slow-growing and aggressive forms of EHE, and thus help us to understand why Sirolimus works in some cases and not in others.